

FIG. 1




FIG. 2




FIG. 3




FIG. 4




Fig. 4A

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit Discuss

Address: Back to Journalsoft Manuscript Management System

My JournalSoft

- [View Manuscripts](#)
- [Personal Data](#)
- [Preferences](#)
- [MetaData](#)
- [Help](#)
- [Logout](#)

Journalsoft

You are logged in with EDITOR privileges.

MANUSCRIPTS TO REVIEW

You have completed 5 reviews. Thank you.
To view the reviews please click on the thumb icons.

YOUR COMPLETED REVIEWS

Legend:
OK = Suggest acceptance.
!OK = Suggest major or minor revisions.
X = Suggest rejection.

<p>99-121 George, Timothy et al. Influence of PZ Immortalization of Human Neuroblasts on P73-Dependent Radiation Responses.</p>	<p>OK Your review received 4 day(s) late on 22-Jan-1999. !OK Other review received on 21-Jan-1999. Declined publication on 21-Jan-1999</p>
<p>99-127 Chinook, Arvin et al. The Apoptosome: Heart and Soul of the Cell Death Machine.</p>	<p>OK Your review received on 19-Jan-1999. Other review received on 16-Jan-1999. Accepted pending minor revision on 19-Jan-1999 Revisions Due by 19-Feb-1999</p>
<p>99-148 Cummings, C.D. et al. The effect of cysteine in combination with vitamin K on the activity of ornithine carbonylase of malignant cells In Vitro.</p>	<p>OK Your review received on 24-Feb-1999. Other review received on 24-Feb-1999. Declined publication on 24-Feb-1999</p>
<p>99-178 Pantaris, Paul et al. The anticancer drug 9-teloscan converts human malignant melanoma cells to a pre-malignant state: Correlation with alterations in the expression of the cyclin-dependent kinase inhibitors.</p>	<p>OK Your review received on 01-Apr-1999. Other review received on 01-Apr-1999. Will reconsider following major revision (02-Apr-1999). Revisions due by 03-May-1999</p>
<p>99-229 Thomas, David et al. Increased expression of the wild type p53 gene in malignant mesotheliomas.</p>	<p>OK Your review received on 10-Jun-1999. Other review received on 08-Jun-1999. Declined publication on 11-Jun-1999</p>

1 Hierarchical Menu Trees Created

Internet

Fig. 4B

File Edit View Favorites Help

Back Forward Stop Refresh Home Search Favorites History Mail

Address Links

Martin Block Paper Sent: 11-Dec-1998 Review Due: 25-Dec-1998 Review Received: 22-Dec-1998

RECOMMENDATION Accept

THIS REVIEW IS MARKED AS A DRAFT.
IT HAS NOT YET BEEN MADE AVAILABLE TO THE EDITORS AND AUTHORS.

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="radio"/>					
Significance	<input type="radio"/>					
Originality	<input type="radio"/>					
Clarity	<input type="radio"/>					

COMMENTS TO THE AUTHORS

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

<U>Specific Comments</U>

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater

THIS REVIEW IS CURRENTLY MARKED AS A DRAFT

Fig. 4C




FIG. 5




FIG. 6

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail

Address: [] Links: []

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Significance	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Originality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Clarity	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

COMMENTS TO THE AUTHORS

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

Specific Comments

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater than 95% inhibited as indicated in the text (p. 8, par. 1).
2. Figure 1: Why are the data for only one experiment shown? It would seem to make more sense to show the data for all experiments with mean and standard errors for each point for the pooled data.

We are sorry that the reviewer seemed confused by this figure. In fact, it was a plot of mean values. We have added error bars and refined the caption to make this more clear.

3. P. 5, par. 3: The use of mean inactivation dose is perhaps the best way to analyze data fitted with the linear-quadratic model, but it is really an arcane method that will not be understood by 95% of the readers. If the authors have to use this method, they should indicate that the method heavily weights the initial part of the survival curve (for example, all data above 10% surviving fraction) and therefore, heavily weights the alpha component

Internet Explorer

Fig. 5A




FIG. 7

FIG. 8

Neoplasia - Manuscript Status - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links

Manuscript Status

NEOPLASIA
An International Journal for Oncology Research

Review-Timeliness Statistics

Rapid peer review is a central goal of the *Neoplasia* Editors.

Currently, the first and second reviews of papers are received and available to authors, on average, 12.1 and 21.7 days after the paper is received, respectively. On average, editorial decisions are made 23.7 days after submission.

Updated 28-Mar-2000.

New user?

[Create An Account](#)

[View a Demonstration](#)

Forget your username or password?

[Retrieve Login Information](#)

Existing Users:
Please logon below:

Username:

Password:

Note that passwords are case-sensitive.

Home Help Feedback Contents Subscribe

Internet

Fig. 9

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links

Fill out the form below completely to register.

1. Your Login Information

Username
Please enter the username you would like to use to login to JournalSoft.

Password
Please enter a password that you can easily remember. Passwords are case-sensitive and should contain between 3 and 10 characters. The most secure passwords contain letters and numbers.
 Please enter your favorite password.
 Confirm password.
 Please enter your main EMAIL address.

You may enter a clue to your password to help you remember it in the future:

Continue

Done Internet

Fig. 10

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links

Fill out the form below completely to register.

2. Enter your contact information below.

Name:	<input type="text"/>		
Address:	<input type="text"/> 		
City, State and Zip Code:	<input type="text"/>	<input type="text"/>	<input type="text"/>
Country:	- Select Continent - <input type="button" value="<"/> <input type="button" value=">"/>		
Phone:	<input type="text"/> (Not Required)		
Fax:	<input type="text"/> (Not Required)		
Text Pager Email or Web Paging Address	<input type="text"/> (Not Required)		
If you have a Web Site, you can include your URL in the AD	Enter exactly as shown here: www.yourdomain.com DO NOT BEGIN YOUR ADDRESS WITH "http://". <input type="text"/>		
<input type="button" value="Continue"/>			

Done Internet

Fig. 11

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links

Fill out the form below completely to register.

3. Please tell us about your research interests

In the space below please write a **SHORT NARRATIVE** about your research interests **OR** enter a list of **KEYWORDS** describing areas of research in which you are interested.

This information will be used to help us assign appropriate reviewers for your submissions and to find papers that you may be interested in reviewing for *Neoplasia* should you agree to serve as a reviewer.

Continue

Done Internet

Fig. 12

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links

Fill out the form below completely to register.

4. Collaborator Communities.

"Collaborator Communities" are groups of your peers with whom you collaborate. JournalSoft provides tools for members of collaborator communities to proof and revise manuscripts on-line prior to submission. They also allow each co-author of a paper to view the manuscript's status in the peer-review process, to view and respond to reviews and editorial decisions, and to contribute to manuscript revisions.

To add people to your collaborator community, please enter their email addresses below. The members of your collaborator community will have access ONLY to those papers on which they are co-authors, or to those for which you explicitly give them permission to view.

Continue

Done Internet

Fig. 13

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links

Journalsoft

To register for JournalSoft, please fill out the form.

Fill out the form below completely to register.

5. JournalSoft Preferences.

Please enter your preferences so we can customize your JournalSoft experience.

Please remember that you can change these options at any time in the future.

Would you like to review papers for Neoplasia?	<input type="radio"/> YES <input checked="" type="radio"/> NO
If so, please enter any dates when you will not be available to review manuscripts (MMDDYY-MMDDYY) Enter each separate period on a new line.	<input type="text"/>
How would you like us to request reviews from you?	<input type="radio"/> On your JournalSoft webpage only. <input type="radio"/> By E-Mail. <input type="radio"/> By Phone. <input type="radio"/> By Fax. <input type="radio"/> By Text Pager.
How would you like us to notify you when a manuscript which you have submitted passes through a peer-review milestone such as a review being received or an editorial decision being made?	<input type="radio"/> On your JournalSoft webpage only. <input type="radio"/> By E-Mail. <input type="radio"/> By Phone. <input type="radio"/> By Fax. <input type="radio"/> By Text Pager.

Continue

Done Internet

Fig. 14




Fig. 15

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Discuss Real.com

Address Links

My JournalSoft

View Manuscripts

Personal Data

Preferences

MetaData

Help

Logout

Journalsoft

You are logged in with EDITOR privileges

CORRESPONDING AUTHOR **CONTRIBUTING AUTHORSHIP**

You are the Corresponding Author for the following 2 manuscripts.
To view or respond to reviews please click on the thumb icons.

99-295
Stegman, Lauren Daniel et al.
Testing Testing 486 .

98-103
Stegman, Lauren Daniel et al.
Collateral Expression of Pro-angiogenic and Tumorigenic Properties In Intestinal Epithelial Cell Variants Selected for Resistance to Anoikis... Research Article

Review 1 received 59 day(s) late on 25-Jan-2000.
Review 2 received 49 day(s) late on 11-Feb-2000.
Review 3 received 296 day(s) late on 03-Jul-1999.

Review 1 received 455 day(s) late on 21-Dec-1998.
Review 2 received 454 day(s) late on 30-Dec-1998.

= Suggest acceptance.
 = Suggest major or minor revisions.
 = Suggest rejection.

[?] Hierarchical Menu Trees Created [?] Internet

Fig. 16

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.